RedHill Biopharma Past Earnings Performance
Past criteria checks 3/6
RedHill Biopharma has been growing earnings at an average annual rate of 11.7%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually. Revenues have been growing at an average rate of 19.6% per year. RedHill Biopharma's return on equity is 1155.9%, and it has net margins of 366.2%.
Key information
11.7%
Earnings growth rate
17.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 19.6% |
| Return on equity | 1,155.9% |
| Net Margin | 366.2% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
RedHill Biopharma Ltd. (NASDAQ:RDHL) Might Not Be As Mispriced As It Looks
Jul 28
One RedHill Biopharma Ltd. (NASDAQ:RDHL) Analyst Has Been Cutting Their Forecasts
Nov 24RedHill Biopharma receives Nasdaq notification regarding minimum bid price deficiency
Oct 18RedHill wins EU’s orphan drug status to RHB-204 for rare lung disease
Aug 17RedHill: Given Up For Dead
Apr 30RedHill Biopharma: Looking At An Unexciting Dead-End
Dec 30RedHill Biopharma Ltd. (NASDAQ:RDHL) Just Reported, And Analysts Assigned A US$15.79 Price Target
Dec 02Revenue & Expenses BreakdownBeta
How RedHill Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 7 | 24 | 31 | 4 |
| 30 Sep 23 | 19 | 34 | 38 | 4 |
| 30 Jun 23 | 36 | 12 | 46 | 5 |
| 31 Mar 23 | 52 | -1 | 55 | 5 |
| 31 Dec 22 | 62 | -72 | 64 | 7 |
| 30 Sep 22 | 71 | -92 | 69 | 12 |
| 30 Jun 22 | 75 | -78 | 79 | 16 |
| 31 Mar 22 | 78 | -95 | 87 | 25 |
| 31 Dec 21 | 86 | -98 | 88 | 29 |
| 30 Sep 21 | 85 | -98 | 95 | 30 |
| 30 Jun 21 | 84 | -95 | 92 | 28 |
| 31 Mar 21 | 84 | -82 | 82 | 21 |
| 31 Dec 20 | 64 | -76 | 75 | 16 |
| 30 Sep 20 | 44 | -64 | 61 | 13 |
| 30 Jun 20 | 25 | -55 | 48 | 11 |
| 31 Mar 20 | 6 | -50 | 38 | 15 |
| 31 Dec 19 | 6 | -42 | 30 | 17 |
| 30 Sep 19 | 6 | -38 | 25 | 21 |
| 30 Jun 19 | 7 | -39 | 21 | 25 |
| 31 Mar 19 | 8 | -39 | 20 | 24 |
| 31 Dec 18 | 8 | -39 | 20 | 25 |
| 30 Sep 18 | 9 | -42 | 21 | 27 |
| 30 Jun 18 | 8 | -47 | 23 | 29 |
| 31 Mar 18 | 6 | -47 | 23 | 31 |
| 31 Dec 17 | 4 | -46 | 20 | 33 |
| 30 Sep 17 | 2 | -43 | 15 | 32 |
| 30 Jun 17 | 1 | -37 | 10 | 31 |
| 31 Mar 17 | 0 | -32 | 6 | 29 |
| 31 Dec 16 | 0 | -29 | 5 | 25 |
| 30 Sep 16 | 0 | -28 | 6 | 23 |
| 30 Jun 16 | 0 | -22 | 5 | 20 |
| 31 Mar 16 | 0 | -22 | 4 | 19 |
| 31 Dec 15 | 0 | -21 | 4 | 18 |
| 30 Sep 15 | 0 | -20 | 4 | 17 |
| 30 Jun 15 | 0 | -21 | 4 | 17 |
| 31 Mar 15 | 0 | -19 | 4 | 15 |
| 31 Dec 14 | 7 | -11 | 4 | 13 |
| 30 Sep 14 | 7 | -9 | 4 | 12 |
| 30 Jun 14 | 7 | -7 | 3 | 10 |
| 31 Mar 14 | 7 | -5 | 3 | 8 |
| 31 Dec 13 | 0 | -11 | 3 | 8 |
| 30 Sep 13 | 0 | -11 | 3 | 7 |
| 30 Jun 13 | 0 | -10 | 3 | 6 |
Quality Earnings: RDHL has a large one-off gain of $54.6M impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: RDHL became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RDHL has become profitable over the past 5 years, growing earnings by 11.7% per year.
Accelerating Growth: RDHL has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: RDHL has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-6.8%).
Return on Equity
High ROE: RDHL's Return on Equity (1155.9%) is considered outstanding.